Triangular Prostatic Stent (TPS)
During the last two decades, the use of prostatic stents has started to become an alternative to indwelling catheters or even to surgery. The adaptation of existing vascular stents for different non-vascular conditions created a gap in the market for site and disease-specific stents that are designed precisely to the anatomy and physiology of the organ to be treated.
The TPS range has a large calibre triangular cross-section to match the contours of the prostatic urethral lumen allowing it to exert varying degrees of radial force depending on the anatomy. For example, higher radial force in its main body and lower radial force in the area near the external sphincter to prevent sphincteric dysfunction. These characteristics enable the TPS to conform to the prostatic urethra, allow an excellent flow and offer a much improved comfort than existing stents, without jeopardising the voluntary continence mechanism.
- Indicated for all prostatic obstructions
- Ambulatory procedure
- Long indwelling time
- Easy insertion under topical anesthesia
- Easy stent positioning
- Excellent stent for prostatic urethral lumen conformation
- Excellent patient comfort
- Excellent voiding control
- Preservation of sexual function
- No tissue in-growth
- Easy stent removal
- Delivery system - 24Fr
- Stent size - 45Fr in lengths of 30mm, 40mm, 50mm or 60mm
Allium TPS—A New Prostatic Stent for the Treatment of Patients with Benign Prostatic Obstruction The First Report - view here
A minimally invasive option for the management for bulbar urethral strictures.
The BUS is a bulbar ...Learn more
The Accoat™ Guide Wire is made from a stainless steel core and can be supplied with or without a PTFE coat. It is ava...Learn more
The Groove Ureteric Stent has been developed using Tecoflex® material, which softe...Learn more
The Longlife Ureteric Stent has been manufactured using Carbothane® polyurethane to aid resistance against constant ...Learn more
From patients undergoing Radical Prostatectomy for localised prostate cancer, up to 18-20% will develop urethro-vesical...Learn more